Literature DB >> 19869830

ON THE PRESENCE IN ANTIPNEUMOCOCCUS SERUM OF TYPE-SPECIFIC PROTECTIVE ANTIBODY NOT NEUTRALIZED BY HOMOLOGOUS SPECIFIC SOLUBLE SUBSTANCE.

A B Sabin1.   

Abstract

The mutual relationship of the anticarbohydrate precipitins and the protective action in antipneumococcus sera to the soluble specific substance was investigated. The assumption is made that there exists in antipneumococcus serum, type-specific protective antibody which is distinct from the anticarbohydrate precipitins and is not neutralized by the soluble specific substance. This assumption is based upon the following observations in experiments which were conducted primarily with Type I antipneumococcus horse serum. 1. Lack of proportionality between the quantity of SSS added and the amount of anticarbohydrate precipitin and protective action neutralized. 2. Protective capacity of specific precipitates (SSS-precipitin complex) is accounted for on the basis of a liberation of non-specifically adsorbed protective antibody. 3. SSS only partially neutralizes the protective action of antipneumococcus serum in vivo. 4. Type-specific protective antibody remains in antipneumococcus serum after complete precipitation of the anticarbohydrate precipitins. 5. This residual type-specific protective antibody is not neutralized by additional SSS nor by absorption with heterologous pneumococci; it is definitely absorbed by the homologous pneumococci.

Entities:  

Year:  1931        PMID: 19869830      PMCID: PMC2131943          DOI: 10.1084/jem.53.1.93

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  CONCENTRATION OF THE PROTECTIVE BODIES IN ANTIPNEUMOCOCCUS SERUM BY MEANS OF SPECIFIC PRECIPITATION.

Authors:  F P Gay; H T Chickering
Journal:  J Exp Med       Date:  1915-04-01       Impact factor: 14.307

2.  THE NEUTRALIZATION OF ANTIPNEUMOCOCCUS IMMUNE BODIES BY INFECTED EXUDATES AND SERA.

Authors:  R Cole
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

3.  STUDIES ON PNEUMOCOCCUS GROWTH INHIBITION : VI. THE SPECIFIC EFFECT OF PNEUMOCOCCUS SOLUBLE SUBSTANCE ON THE GROWTH OF PNEUMOCOCCI IN NORMAL SERUM-LEUCOCYTE MIXTURES.

Authors:  R H Sia
Journal:  J Exp Med       Date:  1926-04-30       Impact factor: 14.307

4.  THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS : THIRD PAPER.

Authors:  M Heidelberger; W F Goebel; O T Avery
Journal:  J Exp Med       Date:  1925-10-31       Impact factor: 14.307

5.  A QUANTITATIVE STUDY OF THE PRECIPITIN REACTION BETWEEN TYPE III PNEUMOCOCCUS POLYSACCHARIDE AND PURIFIED HOMOLOGOUS ANTIBODY.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1929-11-30       Impact factor: 14.307

6.  IMMUNOLOGICAL PROPERTIES OF A TYPICAL (S-PRODUCING) AND A DEGRADED (NON-S-PRODUCING) STRAIN OF TYPE II PNEUMOCOCCUS WITH SPECIAL REFERENCE TO PROTECTIVE ANTIBODIES.

Authors:  E L Gaspari; W L Fleming; J M Neill
Journal:  J Exp Med       Date:  1927-06-30       Impact factor: 14.307

7.  THE ELABORATION OF SPECIFIC SOLUBLE SUBSTANCE BY PNEUMOCOCCUS DURING GROWTH.

Authors:  A R Dochez; O T Avery
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

8.  A TYPE SPECIFIC SUBSTANCE DISTINCT FROM THE SPECIFIC CARBOHYDRATE IN PNEUMOCOCCUS TYPE I.

Authors:  J F Enders
Journal:  J Exp Med       Date:  1930-07-31       Impact factor: 14.307

  8 in total
  6 in total

1.  ON THE USE OF ADSORBENTS IN IMMUNIZATIONS WITH HAPTENS.

Authors:  J Jacobs
Journal:  J Exp Med       Date:  1934-03-31       Impact factor: 14.307

2.  THE PRECIPITIN REACTION OF ANTIPNEUMOCOCCUS SERA : III. THE RATIO OF PRECIPITIN TO PROTECTIVE ANTIBODY IN TYPE II.

Authors:  H Sobotka; M Friedlander
Journal:  J Exp Med       Date:  1931-02-28       Impact factor: 14.307

3.  Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

Authors:  L S McDaniel; J Yother; M Vijayakumar; L McGarry; W R Guild; D E Briles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

4.  Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.

Authors:  L S McDaniel; G Scott; J F Kearney; D E Briles
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

5.  THE IMMUNOLOGICAL RELATIONSHIP OF THE CAPSULAR POLYSACCHARIDE OF TYPE XIV PNEUMOCOCCUS TO THE BLOOD GROUP A SPECIFIC SUBSTANCE.

Authors:  P B Beeson; W F Goebel
Journal:  J Exp Med       Date:  1939-08-31       Impact factor: 14.307

6.  CHEMOIMMUNOLOGICAL STUDIES ON THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS : I. THE ISOLATION AND PROPERTIES OF THE ACETYL POLYSACCHARIDE OF PNEUMOCOCCUS TYPE I.

Authors:  O T Avery; W F Goebel
Journal:  J Exp Med       Date:  1933-11-30       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.